Citations

Clear

4610 citation(s) found for "Lu, Brian".

Mining continuous intracranial EEG in focal canine epilepsy: Relating interictal bursts to seizure onsets
Ung, Hoameng , Wulsin, Drausin, Wagenaar, Joost , Fox, Emily B. , Patterson, Ned, Vite, Charles H. , Litt, Brian , Davis, Kathryn A. , Worrell, Gregory A.

Mayo Clinic

Epilepsia | November 26, 2015 | Volume: 57 | Issue: 1 | Pages: 89-98

10.1111/epi.13249 | PMID 26608448 Get It

SummaryObjectiveBrain regions are localized for resection during epilepsy surgery based on rare seizures observed during a short period of intracranial electroencephalography (iEEG) monitoring. Interictal epileptiform bursts, which are more prevalent than seizures, may provide complementary information to aid in epilepsy evaluation. In this study, we leverage a long‐term iEEG dataset from canines with naturally occurring epilepsy to investigate interictal bursts and their electrographic relationship to seizures.MethodsFour dogs were included in this study, each monitored previously with continuous iEEG for periods of 475.7, 329.9, 45.8, and 451.8 days, respectively, for a total of >11,000 h. Seizures and bursts were detected and validated by two board‐certified epileptologists. A published Bayesian model was applied to analyze the dynamics of interictal epileptic bursts on EEG and compare them to seizures.ResultsIn three dogs, bursts were stereotyped and found to be statistically similar to periods before or near seizure onsets. Seizures from one dog during status epilepticus were markedly different from other seizures in terms of burst similarity.SignificanceShorter epileptic bursts explored in this work have the potential to yield significant information about the distribution of epileptic events. In our data, bursts are at least an order of magnitude more prevalent than seizures and occur much more regularly. Our finding that bursts often display pronounced similarity to seizure onsets suggests that they contain relevant information about the epileptic networks from which they arise and may aide in the clinical evaluation of epilepsy in patients.
Ultrasonic Percutaneous Tenotomy for Recalcitrant Lateral Elbow Tendinopathy
Seng, Chusheng, Mohan, P. Chandra, Koh, Suang Bee, Howe, Tet Sen , Lim, Yee Gen , Morrey, B.F. , Morrey, Bernard F, Mohan, P. Chandra, Lee, Brian P.

Mayo Clinic

The American Journal of Sports Medicine | November 24, 2015 | Volume: 44 | Issue: 2 | Pages: 504-510

10.1177/0363546515612758 | PMID 26602153 Get It

Background: A previously published study found positive outcomes for a novel technique for ultrasound-guided percutaneous ultrasonic tenotomy, showing good tolerability, safety, and early efficacy within an office setting. Purpose: In this follow-up study, all 20 members of the original cohort were contacted after 3 years to explore the sustainability of symptomatic relief, functional improvement, and sonographic soft tissue response for percutaneous ultrasonic tenotomy. Study Design: Case series; Level of evidence, 4. Methods: All 20 subjects of the clinical trial that was performed from June to November 2011 were further assessed at 36 months after the procedure in terms of visual analog scale for pain, Disabilities of the Arm, Shoulder and Hand (DASH)–Compulsory/Work scores, need for adjunct procedures, and overall satisfaction. Importantly, all 20 were reassessed with ultrasound imaging at 36 months, and evidence of the common extensor tendon response was assessed in terms of tendon hypervascularity, tendon thickness, and the progress of the hypoechoic scar tissue. Results: A 100% clinical follow-up was achieved, inclusive of ultrasonographic assessment. None of the subjects required further treatment procedures, and 100% expressed satisfaction. Previous improvements in visual analog scale (current median ± SD, 0 ± 0.9; range, 0-3) and DASH-Work scores (current median, 0 ± 0) were sustained with conformity to a linear pattern on polynomial measures. There was further reduction in DASH-Compulsory scores to a median of 0 ± 0.644 (range, 0-2) with a significant decrease on repeated measures ( P = .008). Tendon hypervascularity was resolved in 94% of patients, and 100% had reduction in tendon thickness. Overall reduction in the hypoechoic scar tissue was observed in all subjects, with a 90% response achieved by 6 months. Between 6 and 36 months, further reduction in the scar was observed in around 60% of patients, with 20% of patients having complete resolution of the hypoechoic scar. Conclusion: Minimally invasive percutaneous ultrasonic tenotomy provided sustained pain relief and functional improvement for recalcitrant tennis elbow at 3-year follow-up. It is one of the few procedures to demonstrate positive sonographic evidence of tissue-healing response and is an attractive alternative to surgical intervention for definitive treatment of recalcitrant elbow tendinopathy.
Hemodynamic Characterization of Geometric Cerebral Aneurysm Templates Treated With Embolic Coils
Nair, Priya , Chong, Brian W. , Indahlastari, Aprinda , Workman, Christopher , Babiker, M. Haithem, Farsani, Hooman Yadollahi, Baccin, Carlos E. , Frakes, David , Ryan, Justin

Mayo Clinic

Journal of Biomechanical Engineering | November 23, 2015 | Volume: 138 | Issue: 2 | Pages: No page available

10.1115/1.4032046 | PMID 26593324 Get It

Embolic coiling is one of the most effective treatments for cerebral aneurysms (CAs), largely due to the hemodynamic modifications that the treatment effects in the aneurysmal environment. However, coiling can have very different hemodynamic outcomes in aneurysms with different geometries. Previous work in the field of biofluid mechanics has demonstrated on a general level that geometry is a driving factor behind aneurysmal hemodynamics. The goal of this study was to relate two specific geometric factors that describe CAs (i.e., dome size (DS) and parent-vessel contact-angle (PV-CA)) and one factor that describes treatment (i.e., coil packing density (PD)) to three clinically relevant hemodynamic responses (i.e., aneurysmal root-mean-square velocity (Vrms), aneurysmal wall shear stress (WSS), and cross-neck flow (CNF)). Idealized models of basilar tip aneurysms were created in both virtual and physical forms to satisfy two-level multifactorial experimental designs. Steady and pulsatile flow hemodynamics were then evaluated in the virtual models using computational fluid dynamics (CFD) (before and after virtual treatment with finite element (FE) embolic coil models), and hemodynamics were also evaluated in the physical models using particle image velocimetry (PIV) (before and after treatment with actual embolic coils). Results showed that among the factors considered, PD made the greatest contributions to effects on hemodynamic responses in and around the aneurysmal sac (i.e., Vrms and WSS), while DS made the greatest contributions to effects on hemodynamics at the neck (i.e., CNF). Results also showed that while a geometric factor (e.g., PV-CA) may play a relatively minor role in dictating hemodynamics in the untreated case, the same factor can play a much greater role after coiling. We consider the significance of these findings in the context of aneurysmal recurrence and rupture, and explore potential roles for the proposed methods in endovascular treatment planning.
Treatment of cytomegalovirus infection and disease pre‐ and post‐quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration?
Dioverti, M. Veronica , Lahr, Brian D. , Lahr, Brian, Razonable, Raymund R. , Dioverti, Maria Veronica

Mayo Clinic

Clinical Transplantation | November 21, 2015 | Volume: 30 | Issue: 2 | Pages: 154-160

10.1111/ctr.12671 | PMID 26589482 Get It

AbstractQuantitative cytomegalovirus (CMV) nucleic acid testing (NAT) has been standardized using the World Health Organization (WHO) international calibration standard. A new FDA‐approved WHO‐calibrated assay (CA) was found to be more sensitive than a laboratory‐developed test (LDT). We hypothesized that monitoring therapeutic response using a more sensitive assay may lead to longer antiviral therapy in solid organ and hematopoietic stem cell transplant patients with CMV infection. We reviewed transplant patients with CMV disease retrospectively, and divided them into two groups: those diagnosed and managed based on LDT and those managed using WHO‐CA. Compared to patients monitored by LDT, the time to reach an undetectable viral load was significantly longer in the group monitored by the WHO‐CA. However, a trend toward shorter duration of antiviral treatment was observed (median, 34 vs. 41 d; p = 0.058), with earlier discontinuation of induction antiviral therapy upon reaching undetectable viral load using WHO‐CA (11 vs. 18 d; p = 002). We concluded that despite using a more sensitive CMV NAT, the total duration of antiviral treatment was not significantly prolonged in transplant patients with CMV infection and disease. Relapse rates did not differ between the two groups.
Tunable tissue scaffolds fabricated by in situ crosslink in phase separation system
Liu, Xifeng , Chen, Wenjian , Gustafson, Carl T., Waletzki, Brian E., Yaszemski, Michael J. , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee

Mayo Clinic

RSC Advances | November 18, 2015 | Volume: 5 | Issue: 122 | Pages: 100824-100833

10.1039/c5ra19406g | PMID 26989479 Get It

A combined method by in situ crosslink polymers under phase separation condition was developed for tunable 3-D porous scaffolds fabrication.
What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?
Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Annals of Neurology | November 17, 2015 | Volume: 79 | Issue: 2 | Pages: 204-205

10.1002/ana.24557 | PMID 26575334 Get It

Successful external cephalic version after preterm premature rupture of membranes utilizing amnioinfusion complicated by fetal femoral fracture
Stanhope, Todd J., Nassr, Ahmed A. , Boldt, Kristi L., El‐Nashar, Sherif A. , Brost, Brian

Mayo Clinic

Case Reports in Perinatal Medicine | November 17, 2015 | Volume: 5 | Issue: 1 | Pages: 23-25

10.1515/crpm-2015-0054 Get It

Abstract We report a case of successful external cephalic version after preterm premature rupture of membranes. Transcervical amnioinfusion was used to facilitate the procedure due to minimal amniotic fluid, and the patient subsequently delivered vaginally. A femoral fracture was later identified in the neonate.
Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta‐analysis
Jonas, Maureen M. , McMahon, Brian J. , Brown, Robert S., Wong, John B. , Ahmed, Ahmed T. , Farah, Wigdan , Mouchli, Mohamed A., Singh, Siddharth , Murad, M. Hassan , Mohammed, Khaled , Murad, Mohammad Hassan, Lok, Anna S. , Prokop, Larry J. , Murad, M Hassan , Farah, Wigdan

Mayo Clinic

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 307-318

10.1002/hep.28278 | PMID 26566163 Get It

Most individuals with chronic hepatitis B viral (HBV) infection acquired the infection around the time of birth or during early childhood. We aimed to synthesize evidence regarding the effectiveness of antiviral therapy in the management of chronic HBV infection in children. We conducted a comprehensive search of multiple databases from 1988 to December 2, 2014, for studies that enrolled children (<18 years) with chronic HBV infection treated with antiviral therapy. We included observational studies and randomized controlled trials (RCTs). Two independent reviewers selected studies and extracted data. In the 14 included studies, two cohort studies showed no significant reduction in the already low risk of hepatocellular carcinoma or cirrhosis and 12 RCTs reported intermediate outcomes. In RCTs with posttreatment follow‐up <12 months, antiviral therapy compared to placebo improved alanine aminotransferase normalization (risk ratio [RR] = 2.3, 95% confidence interval [CI] 1.7‐3.2), hepatitis B e antigen (HBeAg) clearance/loss (RR = 2.1, 95% CI 1.5‐3.1), HBV DNA suppression (RR = 2.9, 95% CI 1.8‐4.6), HBeAg seroconversion (RR = 2.1, 95% CI 1.4‐3.3), and hepatitis B surface antigen clearance (RR = 5.8, 95% CI 1.1‐31.5). In RCTs with posttreatment follow‐up ≥12 months, antiviral therapy improved cumulative HBeAg clearance/loss (RR = 1.9, 95% CI 1.7‐3.1), HBeAg seroconversion (RR = 2.1, 95% CI 1.3‐3.5), alanine aminotransferase normalization (RR = 1.4, 95% CI 1.1‐1.7), and HBV DNA suppression (RR = 1.4, 95% CI 1.1‐1.8) but not hepatitis B surface antigen clearance or seroconversion. Conclusion: In children with chronic HBV infection, antivirals compared to no antiviral therapy improve HBV DNA suppression and frequency of alanine aminotransferase normalization and HBeAg seroconversion. (Hepatology 2016;63:307–318)
Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis
Brown, Robert S., McMahon, Brian J. , Wong, John B. , Ahmed, Ahmed T. , Mouchli, Mohamed A., Murad, M. Hassan , Mohammed, Khaled , Murad, Mohammad Hassan, Lok, Anna S. , Wang, Zhen , Prokop, Larry J. , Murad, M Hassan

Mayo Clinic

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 319-333

10.1002/hep.28302 | PMID 26565396 Get It

Perinatal or mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk factor for chronic HBV infection worldwide. In addition to hepatitis B immune globulin and vaccination, oral antiviral therapies in highly viremic mothers can further decrease MTCT of HBV. We conducted a systematic review and meta‐analysis to synthesize the evidence on the efficacy and maternal and fetal safety of antiviral therapy during pregnancy. A protocol was developed by the American Association for the Study of Liver Diseases guideline writing committee. We searched multiple databases for controlled studies that enrolled pregnant women with chronic HBV infection treated with antiviral therapy. Outcomes of interest were reduction of MTCT and adverse outcomes to mothers and newborns. Study selection and data extraction were done by pairs of independent reviewers. We included 26 studies that enrolled 3622 pregnant women. Antiviral therapy reduced MTCT, as defined by infant hepatitis B surface antigen seropositivity (risk ratio = 0.3, 95% confidence interval 0.2‐0.4) or infant HBV DNA seropositivity (risk ratio = 0.3, 95% confidence interval 0.2‐0.5) at 6‐12 months. No significant differences were found in the congenital malformation rate, prematurity rate, and Apgar scores. Compared to control, lamivudine or telbivudine improved maternal HBV DNA suppression at delivery and during 4‐8 weeks' postpartum follow‐up. Tenofovir showed improvement in HBV DNA suppression at delivery. No significant differences were found in postpartum hemorrhage, cesarean section, and elevated creatinine kinase rates. Conclusions: Antiviral therapy improves HBV suppression and reduces MTCT in women with chronic HBV infection with high viral load compared to the use of hepatitis B immunoglobulin and vaccination alone; the use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnancy with no increased adverse maternal or fetal outcome. (Hepatology 2016;63:319–333)
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
McMahon, Brian J. , Brown, Robert S., Wong, John B. , Ahmed, Ahmed T. , Farah, Wigdan , Almasri, Jehad , Alahdab, Fares , Benkhadra, Khalid, Mouchli, Mohamed A., Singh, Siddharth , Mohamed, Essa A. , Dabrh, Abd Moain Abu , Murad, M. Hassan , Mohammed, Khaled , Abu Dabrh, Abd Moain, Murad, Mohammad Hassan, Lok, Anna S. , Prokop, Larry J. , Wang, Zhen , Murad, M Hassan , Abu Dabrh, Abd Moain , Farah, Wigdan , Alahdab, Fares

Mayo Clinic

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 284-306

10.1002/hep.28280 | PMID 26566246 Get It

Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence‐based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped. The American Association for the Study of Liver Diseases HBV guideline methodology and writing committees developed a protocol a priori for this systematic review. We searched multiple databases for randomized controlled trials and controlled observational studies that enrolled adults ≥18 years old diagnosed with chronic HBV infection who received antiviral therapy. Data extraction was done by pairs of independent reviewers. We included 73 studies, of which 59 (15 randomized controlled trials and 44 observational studies) reported clinical outcomes. Moderate‐quality evidence supported the effectiveness of antiviral therapy in patients with immune active chronic HBV infection in reducing the risk of cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In immune tolerant patients, moderate‐quality evidence supports improved intermediate outcomes with antiviral therapy. Only very low‐quality evidence informed the questions about discontinuing versus continuing antiviral therapy in hepatitis B e antigen‐positive patients who seroconverted from hepatitis B e antigen to hepatitis B e antibody and about the safety of entecavir versus tenofovir. Noncomparative and indirect evidence was available for questions about stopping versus continuing antiviral therapy in hepatitis B e antigen‐negative patients, monotherapy versus adding a second agent in patients with persistent viremia during treatment, and the effectiveness of antivirals in compensated cirrhosis with low‐level viremia. Conclusion: Most of the current literature focuses on the immune active phases of chronic HBV infection; decision‐making in other commonly encountered and challenging clinical settings depends on indirect evidence. (H epatology 2016;63:284–306)